A clinical trial involving degarelix has changed status to completed as of September 2, 2026. The study, titled "TRial on the Endocrine Activity of Neoadjuvant Degarelix," is registered under identifier NCT02005887. It was conducted as a Phase 2 trial.
According to the available record, the trial's status is listed as completed. The registration does not provide additional detail on outcomes, results, or findings associated with this update. No efficacy or safety conclusions are included in the available data for this event.
Degarelix is an approved compound, and this trial update reflects a change in the study's recorded status on clinicaltrials.gov rather than a new safety or efficacy finding. Readers should note that a completed status indicates the trial has concluded per its registration, without implying any particular result unless separately reported.
This entry is based solely on the trial registration data provided and does not include interpretation of clinical significance. For those seeking additional context on degarelix, including its approved uses and regulatory background, further information is available on the compound overview page.